Fukagawa M, Komaba H. Chronic kidney disease-mineral and bone disorder in Asia. Kidney Dis (Basel). 2017;3(1):1–7. https://doi.org/10.1159/000470909.
Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J. 2016;9(4):583–91. https://doi.org/10.1093/ckj/sfw047.
Article PubMed PubMed Central Google Scholar
Shroff R, Wesseling-Perry K, Bacchetta J. Chronic kidney disease – mineral and bone disorder (CKD-MBD). In: Emma F, Goldstein SL, Bagga A, Bates CM, Shroff R, editors. Pediatric Nephrology. Berlin: Springer; 2002. pp. 1755–83. https://doi.org/10.1007/978-3-030-52719-8_129.
Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M, et al. Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; a post-hoc analysis of a randomized clinical trial. PLoS ONE. 2018;13(10):e0205831. https://doi.org/10.1371/journal.pone.0205831.
Article CAS PubMed PubMed Central Google Scholar
Lalayiannis AD, Crabtree NJ, Ferro CJ, Wheeler DC, Duncan ND, Smith C, et al. Bone mineral density and vascular calcification in children and young adults with CKD 4 to 5 or on dialysis. Kidney Int Rep. 2022;8(2):265–73. https://doi.org/10.1016/j.ekir.2022.10.023.
Article PubMed PubMed Central Google Scholar
Lawal OM, Balogun MO, Akintomide AO, Ayoola OO, Mene-Afejuku TO, Ogunlade O, et al. Carotid intima-media thickness: a surrogate marker for cardiovascular disease in chronic kidney disease patients. Clin Med Insights Cardiol. 2019;13:1179546819852941. https://doi.org/10.1177/1179546819852941.
Article PubMed PubMed Central Google Scholar
Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, et al. Cardiovascular phenotypes in children with CKD: the 4 C study. Clin J Am Soc Nephrol. 2017;12(1):19–28. https://doi.org/10.2215/CJN.01090216.
Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, et al. Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol. 2012;7(12):1930–7. https://doi.org/10.2215/CJN.03130312.
Article PubMed PubMed Central Google Scholar
Lopes R, Morais MB, Oliveira FLC, Brecheret AP, Abreu ALCS, Andrade MC. Evaluation of carotid intima-media thickness and factors associated with cardiovascular disease in children and adolescents with chronic kidney disease. J Pediatr (Rio J). 2019 Nov-Dec;95(6):696–704. https://doi.org/10.1016/j.jped.2018.06.010.
Husen M, Fischer A, Lehnhardt A, Klaassen I, Moller K, Muller-Wiefel D, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 2010;78(2):200–6. https://doi.org/10.1038/ki.2010.107.
Article CAS PubMed Google Scholar
Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370–8. https://doi.org/10.1038/ki.2011.47.
Article CAS PubMed PubMed Central Google Scholar
Palupi-Baroto R, Hermawan K, Murni IK, Nurlitasari T, Prihastuti Y, Sekali DRK, et al. High fibroblast growth factor 23 as a biomarker for severe cardiac impairment in children with chronic kidney disease: a single tertiary center study. Int J Nephrol Renovasc Dis. 2021;14:165–71. https://doi.org/10.2147/IJNRD.S304143.
Article CAS PubMed PubMed Central Google Scholar
Naveh-Many T, Silver J. The pas de trois of vitamin D, FGF23, and PTH. J Am Soc Nephrol. 2017;28(2):393–5. https://doi.org/10.1681/ASN.2016090944.
Article CAS PubMed Google Scholar
Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol. 2013;9(11):641–9. https://doi.org/10.1038/nrneph.2013.147.
Article CAS PubMed Google Scholar
Albanese L, Caliendo G, D’Elia G, Passariello L, Molinari AM, Napoli C, et al. Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease. J Circ Biomark. 2022;11:1–4. https://doi.org/10.33393/jcb.2022.2328.
Article CAS PubMed PubMed Central Google Scholar
Kurpas A, Supeł K, Idzikowska K, Zielińska M. FGF23: a review of its role in mineral metabolism and renal and cardiovascular disease. Dis Markers. 2021;2021:8821292. https://doi.org/10.1155/2021/8821292.
Article CAS PubMed PubMed Central Google Scholar
Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009;94(2):511–7. https://doi.org/10.1210/jc.2008-0326.
Article CAS PubMed Google Scholar
Leifheit-Nestler M, Haffner D. How FGF23 shapes multiple organs in chronic kidney disease. Mol Cell Pediatr. 2021;8(1):12. https://doi.org/10.1186/s40348-021-00123-x.
Article PubMed PubMed Central Google Scholar
Hanudel MR, Salusky IB. Treatment of pediatric chronic kidney disease-mineral and bone disorder. Curr Osteoporos Rep. 2017;15(3):198–206. https://doi.org/10.1007/s11914-017-0365-0.
Article PubMed PubMed Central Google Scholar
Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7(1):146–52. https://doi.org/10.2215/CJN.05940611.
Article CAS PubMed Google Scholar
Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011;26(6):945–51. https://doi.org/10.1007/s00467-011-1822-0.
Singh G, Mishra OP, Abhinay A, Agarwal V, Mishra SP, Dwivedi AD, et al. Fibroblast growth factor 23 level and cardiovascular parameters in children with chronic kidney disease. Indian J Pediatr. 2022;89(9):865–71. https://doi.org/10.1007/s12098-021-03927-x.
Preka E, Ranchin B, Doyon A, Vierge M, Ginhoux T, Kassai B, et al. The interplay between bone and vessels in pediatric CKD: lessons from a single-center study. Pediatr Nephrol. 2018;33(9):1565–75. https://doi.org/10.1007/s00467-018-3978-3.
KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2013;3:1–150. https://doi.org/10.1038/kisup.2012.77.
KDIGO Executive Committee. KDIGO 2023 clinical practice guideline for the evaluation and management of chronic kidney disease.
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. https://doi.org/10.1542/peds.2017-1904.
Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, et al. Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol. 2016;11(11):1989–98. https://doi.org/10.2215/CJN.02110216.
Article CAS PubMed PubMed Central Google Scholar
Jančič SG, Močnik M, Marčun Varda N. Glomerular filtration rate assessment in children. Child (Basel). 2022;9(12):1995. https://doi.org/10.3390/children9121995.
Drole Torkar A, Plesnik E, Groselj U, Battelino T, Kotnik P. Carotid intima-media thickness in healthy children and adolescents: normative data and systematic literature review. Front Cardiovasc Med. 2020;7:597768. https://doi.org/10.3389/fcvm.2020.597768.
Article PubMed PubMed Central Google Scholar
Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93–quiz111189. https://doi.org/10.1016/j.echo.2007.11.011.
留言 (0)